R. Wilmott (St. Louis, United States of America), A. Lindblad (Savedalen, Sweden)
Late Breaking Abstract: Denufosol: A novel ion channel regulator and investigational early-intervention therapy for cystic fibrosis
M. J. Stutts, M. S. Cowlen, S. F. Okada, R. C. Boucher (Durham, Chapel Hill, United States Of America)
|   |
LSC 2010 Abstract: Ceramide is increased and associated with neutrophilic inflammation in the lower airway epithelium of people with cystic fibrosis
M. Brodlie, M. C. McKean, G. Johnson, A. J. Fisher, P. A. Corris, J. Lordan, C. Ward (Newcastle upon Tyne, United Kingdom)
| |
Deficiency of the glutathione anti-oxidant defence system in young children with cystic fibrosis
P. Sly, C. Gangell, A. Kettle, C. F. Arest (Perth, Australia; Christchurch, New Zealand)
| |
Analysis of CFTR function in human monocytes
J. Johansson, C. Sorio, M. Buffelli, M. Ettorre, M. Vezzalini, M. Ricciardi, C. Angiari, B. Assael, P. Melotti (Verona, Italy)
| |
Elucidating the cellular responses of healthy and cystic fibrosis (CF) airway epithelial cells in response to non-viral stimuli and human rhinoviral (HRV) infection
C. J. Foo, E. N. Sutanto, A. Kicic, S. M. Stick (Perth, Australia)
| |
Influenza A/H1N1virus infection in CF compared to other risk groups
I. De Schutter, E. De Wachter, F. Van Ginderdeuren, S. Vanlaethem, O. Soetens, I. Wybo, D. Pierard, A. Malfroot (Belgium)
| |
Inflammatory responses to individual organisms in the lungs of children with cystic fibrosis
C. Gangell, G. Samantha, D. Tonia, N. de Klerk, K. Tony, B. Siobhain, R. Sarath, R. Robins-Browne, S. Peter, C. F. Arest (Perth, Melbourne, Australia)
| |
Serial change in serum KL-6 levels correlate with the pulmonary function variables in cystic fibrosis
S. Ohshimo, F. Bonella, H. Teschler, N. Kohno, J. Guzman, U. Costabel (Essen, Germany; , Japan)
| |
Influence of leucocytes on Interleukin-8 (IL-8) in sputum and whole blood in cystic fibrosis
S. Schmitt-Grohé, L. van den Boom, D. N‘Gampolo, O. Eickmeier, R. Schubert, S. Zielen, Z. Bernd, M. Lentze (Bonn, Frankfurt, Germany)
| |
Matrix metalloproteinase (MMP) 12 is not associated with clinical parameters of severity in cystic fibrosis (CF)
G. Devereux, S. Steele, R. Muirhead, J. Brady, R. Brooker, D. Miller (Aberdeen, Dundee, United Kingdom; Collegeville, United States Of America)
| |
Matrix metalloproteinase (MMP) 9 is associated with clinical parameters of severity in cystic fibrosis (CF)
G. Devereux, S. Steele, R. Muirhead, J. Brady, R. Brooker, D. Miller (Aberdeen, Dundee, United Kingdom; Collegeville, United States Of America)
| |
Association of exhaled breath condensate pH with markers of neutrophilic inflammation in bronchoalveolar lavage in young children with cystic fibrosis
F. Horak, Jr., T. Eiwegger, S. Cermak, S. Gruber, S. Renner, M. Hörmann, M. Gona, P. Fucik, E. Nachbaur, Z. Szepfalusi, T. Frischer (Austria; Davos, Switzerland)
| |
Impact of standardised chest physiotherapy with high frequency chest wall oscillation on lung clearance index in sputum producing patients with cystic fibrosis
J. Grosse-Onnebrink, F. Stehling, U. Mellies (Germany)
| |
Effects of individualised aerobic exercise training in adults with cystic fibrosis
M. Petrovic, I. Kaluza, W. Pohl (Vienna, Austria)
| |
Comparison of HRCT lung abnormalities with exercise capacity among children and adolescents with cystic fibrosis
E. Hatziagorou, K. Kontouli, V. Georgopoulou, F. Kirvassilis, V. Avramidou, A. Mavroudi, J. Tsanakas (Thessaloniki, Greece)
| |
Management of patients with cystic fibrosis: Role of non invasive ventilation (NIV) and chest physiotherapy
A. Petrone, M. Quartieri, F. Tirone, C. Tirone, G. Francesco Mauro (San Giovanni in Fiore, Castrovillari, Italy)
| |
Prevalence of anxiety and association with health related quality of life in adult patients with cystic fibrosis
A. M. Yohannes, T. Willgoss, M. Dodd, F. Fatoye, K. Webb (United Kingdom)
| |
Efficacy of alendronate/colecalciferol/calcium in adults with cystic fibrosis
S. Krasovsky, I. Baranova, N. Demin, E. Amelina (Moscow, Russian Federation)
| |